Department of Neurosurgery, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands; and.
Department of Radiation Sciences, Oncology, Umea University, Umea, Sweden.
Blood. 2021 Jun 10;137(23):3181-3191. doi: 10.1182/blood.2019003978.
Until recently, the nucleic acid content of platelets was considered to be fully determined by their progenitor megakaryocyte. However, it is now well understood that additional mediators (eg, cancer cells) can intervene, thereby influencing the RNA repertoire of platelets. Platelets are highly dynamic cells that are able to communicate and influence their environment. For instance, platelets have been involved in various steps of cancer development and progression by supporting tumor growth, survival, and dissemination. Cancer cells can directly and/or indirectly influence platelet RNA content, resulting in tumor-mediated "education" of platelets. Alterations in the tumor-educated platelet RNA profile have been described as a novel source of potential biomarkers. Individual platelet RNA biomarkers as well as complex RNA signatures may be used for early detection of cancer and treatment monitoring. Here, we review the RNA transfer occurring between cancer cells and platelets. We explore the potential use of platelet RNA biomarkers as a liquid biopsy biosource and discuss methods to evaluate the transcriptomic content of platelets.
直到最近,人们一直认为血小板的核酸含量完全由其前体细胞巨核细胞决定。然而,现在人们已经清楚地认识到,其他介质(例如癌细胞)可以介入,从而影响血小板的 RNA 谱。血小板是高度动态的细胞,能够进行通讯并影响其环境。例如,血小板通过支持肿瘤生长、存活和扩散而参与癌症发展和进展的各个阶段。癌细胞可以直接和/或间接地影响血小板的 RNA 含量,从而导致肿瘤对血小板进行“教育”。肿瘤教育的血小板 RNA 谱的改变被描述为一种潜在的生物标志物的新来源。单个血小板 RNA 生物标志物和复杂的 RNA 特征可用于癌症的早期检测和治疗监测。在这里,我们回顾了癌细胞和血小板之间发生的 RNA 转移。我们探讨了将血小板 RNA 生物标志物用作液体活检生物源的潜在用途,并讨论了评估血小板转录组含量的方法。